Xeljanz XR 11 MG tablet UU 30S
Ended Awarded
- Contract number
- SPE2DB26FAUAF
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $15,417
Award facts
- Contract value 100% obligated
- $15,416.93 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $15,416.93 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xeljanz XR 11 mg tablets (30-count units). The delivery order, issued on October 29, 2025, with an ultimate completion date of October 30, 2025, represents a firm fixed-price contract with no set-aside designation, indicating the vendor competed in an unrestricted procurement environment. Performance will occur in Conshohocken, Pennsylvania. This award falls under DMS Pharmaceutical Group's broader Indefinite Delivery Contract (IDC) with the DLA, specifically the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical procurement across the Department of Defense's military healthcare system.
DMS Pharmaceutical Group has established itself as a critical pharmaceutical supplier within the federal military medical system, maintaining active contract performance with the DLA's Medical Supply Chain division since 2001. The company's comprehensive product portfolio spans branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables. The PPV-G GEN V IDC, valued at $499.9 million with a completion date of December 31, 2036, authorizes the DLA to issue firm fixed-price delivery orders for pharmaceutical products supporting recurring medical supply needs of military healthcare facilities worldwide. No subcontractors have been identified in the award documentation, with DMS Pharmaceutical Group serving as the sole prime contractor responsible for fulfilling the company's established pharmaceutical supply obligations to Department of Defense operations globally.
Quick answers
Who was awarded contract SPE2DB26FAUAF?
SPE2DB26FAUAF was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 29, 2025.
How much is contract SPE2DB26FAUAF worth?
The government has obligated $15,417 on SPE2DB26FAUAF.
Is contract SPE2DB26FAUAF an order under another contract?
Yes. SPE2DB26FAUAF is a delivery order under SPE2DB24D2106, an indefinite delivery contract.
Was contract SPE2DB26FAUAF competed?
The extent of competition for SPE2DB26FAUAF was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award